Novabay Pharmaceuticals Inc Anno IPO
Cos'è Anno IPO di Novabay Pharmaceuticals Inc?
Anno IPO di Novabay Pharmaceuticals Inc è 2007
Qual è la definizione di Anno IPO?
L'offerta pubblica iniziale è un tipo di offerta pubblica in cui le azioni di una società di solito sono vendute a investitori istituzionali che, a loro volta, vendono al pubblico in generale, su una borsa valori, per la prima volta.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Anno IPO di aziende nel Health Care settore su NYSEMKT rispetto a Novabay Pharmaceuticals Inc
Cosa fa Novabay Pharmaceuticals Inc?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Aziende con anno ipo simili a Novabay Pharmaceuticals Inc
- G3 Exploration ha Anno IPO di 2006
- Evolis SA ha Anno IPO di 2006
- Unity Infraprojects ha Anno IPO di 2006
- News Invest ha Anno IPO di 2006
- AuStar Gold ha Anno IPO di 2006
- Sky and Space Global ha Anno IPO di 2006
- Novabay Pharmaceuticals Inc ha Anno IPO di 2007
- Manas Resources ha Anno IPO di 2008
- Mastech Digital Inc ha Anno IPO di 2008
- MYR Inc ha Anno IPO di 2008
- Dana Inc ha Anno IPO di 2008
- American Water Works Co ha Anno IPO di 2008
- Chromadex Corp ha Anno IPO di 2008